Simulations Plus, Inc. Forms Scientific Advisory Board for RENAsym Consortium
March 16, 2021 at 08:30 am EDT
Share
Simulations Plus, Inc. announced that company has formed Scientific Advisory Board within the RENAsym Consortium, and consists of the following experts: Dr. Lauren Aleksunes, Professor of Pharmacology and Toxicology at the Rutgers University Ernest Mario School of Pharmacy; Dr. Zheng Dong, Regents’ Professor and Leon H. Charbonnier Endowed Chair at the Medical College of Georgia of Augusta University and the Director of Research & Development at the Charlie Norwood VA Medical Center; Dr. K. Melissa Hallow, Associate Professor at the University of Georgia School of Chemical, Materials, and Biomedical Engineering; Dr. Ravindra Mehta, Professor at the University of California at San Diego School of Medicine; Dr. Frank D. Sistare, Former Scientific Associate Vice President at Merck Research Laboratories and Captain in the U.S.Public Health Service at the Food and Drug Administration’s Center for Drug Evaluation and Research; Dr. Paul B. Watkins, RENAsym and DILI-sim SAB Chair, Howard Q. Ferguson Distinguished Professor and Director of the Institute for Drug Safety Sciences at the University of North Carolina.
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.